Pictured left to right: P. McKiernan, A. Soto-Gutierrez, J. Squires, R. Squires
James E. Squires, Kyle A. Soltys, Patrick McKiernan, Robert H. Squires, Stephen C. Strom, Ira J. Fox, Alejandro Soto-Gutierrez. “Clinical Hepatocyte Transplantation: What Is Next?” Curr Transpl Rep (2017). https://doi.org/10.1007/s40472-017-0165-6.
ABSTRACT: Purpose of Review – Significant recent scientific developments have occurred in the field of liver repopulation and regeneration. While techniques to facilitate liver repopulation with donor hepatocytes and different cell sources have been studied extensively in the laboratory, in recent years, clinical hepatocyte transplantation (HT) and liver repopulation trials have demonstrated new disease indications and also immunological challenges that will require the incorporation of a fresh look and new experimental approaches.
Recent Findings – Growth advantage and regenerative stimulus are necessary to allow donor hepatocytes to proliferate. Current research efforts focus on mechanisms of donor hepatocyte expansion in response to liver injury/preconditioning. Moreover, the latest clinical evidence shows that important obstacles to HT include optimizing engraftment and limited duration of effectiveness, with hepatocytes being lost to immunological rejection. We will discuss alternatives for cellular rejection monitoring, as well as new modalities to follow cellular graft function and near-to-clinical cell sources.
Summary – HT partially corrects genetic disorders for a limited period of time and has been associated with reversal of acute liver failure. The main identified obstacles that remain to make HT a curative approach include improving engraftment rates, and methods for monitoring cellular graft function and rejection. This review aims to discuss current state of the art in clinical HT and provide insights into innovative approaches taken to overcome these obstacles.
